DDInter743 DDInter1435
Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Fluconazole {u} (Compound) binds {v} (Gene) CYP3A7
Fluconazole {u} (Compound) upregulates {v} (Gene) MELK
Fluconazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Fluconazole {u} (Compound) downregulates {v} (Gene) WFS1
Fluconazole {u} (Compound) causes {v} (Side Effect) Rigors
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ulipristal
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abarelix
Fluconazole {u} may lead to a major life threatening interaction when taken with {v} Ivacaftor
Fluconazole {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voriconazole
Fluconazole (Compound) binds CYP3A7 (Gene)
Fluconazole (Compound) upregulates MELK (Gene)
Fluconazole (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Fluconazole (Compound) downregulates WFS1 (Gene)
Fluconazole (Compound) causes Rigors (Side Effect)
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Abarelix
Fluconazole may lead to a major life threatening interaction when taken with Ivacaftor
Fluconazole (Compound) resembles Voriconazole (Compound) and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole